Table of contents
Volume 101, Issue 8
Published online 13 October 2009 (1225-1490)
Clinical Studies |
Translational Therapeutics |
Molecular Diagnostics |
Genetics and Genomics |
Letter to the Editor
Minireview
Imaging metastatic bone disease from carcinoma of the prostate FREE
C Messiou, G Cook and N M deSouza
Br J Cancer 101: 1225-1232; advance online publication, September 29, 2009; doi:10.1038/sj.bjc.6605334
Clinical Studies
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
O Bratt, M Häggman, G Ahlgren, Ö Nordle, A Björk and J-E Damber
Br J Cancer 101: 1233-1240; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605322
Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial
D Arnold, W Voigt, P Kiewe, C Behrmann, S Lindemann, S Reif, H Wiesinger, M Giurescu, E Thiel and H-J Schmoll
Br J Cancer 101: 1241-1247; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605327
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
B Mellado, A Font, A Alcaraz, L A Aparicio, F J G Veiga, J Areal, E Gallardo, N Hannaoui, J R M Lorenzo, A Sousa, P L Fernandez and P Gascon
Br J Cancer 101: 1248-1252; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605320
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
M Hauglid Flågeng, L L Haugan Moi, J M Dixon, J Geisler, E A Lien, W R Miller, P E Lønning and G Mellgren
Br J Cancer 101: 1253-1260; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605324
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
C Pinto, F Di Fabio, C Barone, S Siena, A Falcone, S Cascinu, F L Rojas Llimpe, G Stella, G Schinzari, S Artale, V Mutri, S Giaquinta, L Giannetta, A Bardelli and A A Martoni
Br J Cancer 101: 1261-1268; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605319
Evaluation of bowel cancer registration data in England, 1996–2004
A M Jones, E Morris, J Thomas, D Forman, J Melia and S M Moss
Br J Cancer 101: 1269-1273; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605321
Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme
L G M van Rossum, A F van Rijn, R J F Laheij, M G H van Oijen, P Fockens, J B M J Jansen, A L M Verbeek and E Dekker
Br J Cancer 101: 1274-1281; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605326
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
Ø Fluge, K Gravdal, E Carlsen, B Vonen, K Kjellevold, S Refsum, R Lilleng, T J Eide, T B Halvorsen, K M Tveit, A P Otte, L A Akslen and O Dahl for the Norwegian Gastrointestinal Cancer Group
Br J Cancer 101: 1282-1289; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605333
Translational Therapeutics
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
D L Roberts, K J Williams, R L Cowen, M Barathova, A J Eustace, S Brittain-Dissont, M J Tilby, D G Pearson, C J Ottley, I J Stratford and C Dive
Br J Cancer 101: 1290-1297; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605311
Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus
T Makino, M Yamasaki, A Takeno, M Shirakawa, H Miyata, S Takiguchi, K Nakajima, Y Fujiwara, T Nishida, N Matsuura, M Mori and Y Doki
Br J Cancer 101: 1298-1306; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605313
Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
Y Andersson, O Engebraaten and Ø Fodstad
Br J Cancer 101: 1307-1315; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605312
Glucocorticoid therapy and risk of bladder cancer
K Dietrich, A Schned, J Fortuny, J Heaney, C Marsit, K T Kelsey and M R Karagas
Br J Cancer 101: 1316-1320; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605314
Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
M Shehata, A Mukherjee, S Deen, A Al-Attar, L G Durrant and S Chan
Br J Cancer 101: 1321-1328; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605315
Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer FREE
F Castro, B Leal, A Denny, R Bahar, S Lampkin, R Reddick, S Lu and C Gravekamp
Br J Cancer 101: 1329-1337; advance online publication, September 29, 2009; doi:10.1038/sj.bjc.6605329
Molecular Diagnostics
Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival
S J Dawson, S W Duffy, F M Blows, K E Driver, E Provenzano, J LeQuesne, D C Greenberg, P Pharoah, C Caldas and G C Wishart
Br J Cancer 101: 1338-1344; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605317
Human papilloma virus is associated with breast cancer FREE
B Heng, W K Glenn, Y Ye, B Tran, W Delprado, L Lutze-Mann, N J Whitaker and J S Lawson
Br J Cancer 101: 1345-1350; advance online publication, September 1, 2009; doi:10.1038/sj.bjc.6605282
Koilocytes indicate a role for human papilloma virus in breast cancer
J S Lawson, W K Glenn, B Heng, Y Ye, B Tran, L Lutze-Mann and N J Whitaker
Br J Cancer 101: 1351-1356; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605328
Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
F Végran, R Boidot, B Coudert, P Fumoleau, L Arnould, J Garnier, S Causeret, J Fraise, D Dembélé and S Lizard-Nacol
Br J Cancer 101: 1357-1364; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605310
Direct cancer–stromal interaction increases fibroblast proliferation and enhances invasive properties of scirrhous-type gastric carcinoma cells
S Semba, Y Kodama, K Ohnuma, E Mizuuchi, R Masuda, M Yashiro, K Hirakawa and H Yokozaki
Br J Cancer 101: 1365-1373; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605309
Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells
K Ueno, S Hazama, S Mitomori, M Nishioka, Y Suehiro, H Hirata, M Oka, K Imai, R Dahiya and Y Hinoda
Br J Cancer 101: 1374-1381; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605307
CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer
A Lugli, E Karamitopoulou, I Panayiotides, P Karakitsos, G Rallis, G Peros, G Iezzi, G Spagnoli, M Bihl, L Terracciano and I Zlobec
Br J Cancer 101: 1382-1392; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605318
Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma
A Birgersdotter, K R N Baumforth, A Porwit, J Sjöberg, W Wei, M Björkholm, P G Murray and I Ernberg
Br J Cancer 101: 1393-1401; advance online publication, September 22, 2009; doi:10.1038/sj.bjc.6605238
Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling
V Zismanov, M Lishner, S Tartakover-Matalon, J Radnay, H Shapiro and L Drucker
Br J Cancer 101: 1402-1409; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605291
DKC1 overexpression associated with prostate cancer progression
P Sieron, C Hader, J Hatina, R Engers, A Wlazlinski, M Müller and W A Schulz
Br J Cancer 101: 1410-1416; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605299
Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
J-J Patard, N Rioux-Leclercq, D Masson, S Zerrouki, F Jouan, N Collet, C Dubourg, B Lobel, M Denis and P Fergelot
Br J Cancer 101: 1417-1424; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605298
Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas
M Murase, M Kano, T Tsukahara, A Takahashi, T Torigoe, S Kawaguchi, S Kimura, T Wada, Y Uchihashi, T Kondo, T Yamashita and N Sato
Br J Cancer 101: 1425-1432; advance online publication, September 29, 2009; doi:10.1038/sj.bjc.6605330
Overexpression of FOXG1 contributes to TGF-
resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer
D W Chan, V W S Liu, R M Y To, P M Chiu, W Y W Lee, K M Yao, A N Y Cheung and H Y S Ngan
Br J Cancer 101: 1433-1443; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605316
Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma
V Koljonen, H Kukko, E Pukkala, R Sankila, T Böhling, E Tukiainen, H Sihto and H Joensuu
Br J Cancer 101: 1444-1447; advance online publication, September 15, 2009; doi:10.1038/sj.bjc.6605306
Genetics and Genomics
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
R J Flockhart, J L Armstrong, N J Reynolds and P E Lovat
Br J Cancer 101: 1448-1455; advance online publication, September 1, 2009; doi:10.1038/sj.bjc.6605277
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
O M Sinilnikova, A C Antoniou, J Simard, S Healey, M Léoné, D Sinnett, A B Spurdle, J Beesley, X Chen, kConFab, M H Greene, J T Loud, F Lejbkowicz, G Rennert, S Dishon, I L Andrulis, OCGN, S M Domchek, K L Nathanson, S Manoukian, P Radice, I Konstantopoulou, I Blanco, A L Laborde, M Durán, A Osorio, J Benitez, U Hamann, F B L Hogervorst, T A M van Os, H J P Gille, HEBON, S Peock, M Cook, C Luccarini, D G Evans, F Lalloo, R Eeles, G Pichert, R Davidson, T Cole, J Cook, J Paterson, C Brewer, EMBRACE, D J Hughes, I Coupier, S Giraud, F Coulet, C Colas, F Soubrier, E Rouleau, I Bièche, R Lidereau, L Demange, C Nogues, H T Lynch, GEMO, R K Schmutzler, B Versmold, C Engel, A Meindl, N Arnold, C Sutter, H Deissler, D Schaefer, U G Froster, GC-HBOC, K Aittomäki, H Nevanlinna, L McGuffog, D F Easton, G Chenevix-Trench and D Stoppa-Lyonnet on behalf of the Consortium of Investigators of Modifiers of BRCA1/2
Br J Cancer 101: 1456-1460; advance online publication, August 25, 2009; doi:10.1038/sj.bjc.6605279
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis
J M Cunningham, R A Vierkant, T A Sellers, C Phelan, D N Rider, M Liebow, J Schildkraut, A Berchuck, F J Couch, X Wang, B L Fridley, Ovarian Cancer Association Consortium, A Gentry-Maharaj, U Menon, E Hogdall, S Kjaer, A Whittemore, R DiCioccio, H Song, S A Gayther, S J Ramus, P D P Pharaoh and E L Goode
Br J Cancer 101: 1461-1468; advance online publication, September 8, 2009; doi:10.1038/sj.bjc.6605284
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis
R Fernández-Ramires, X Solé, L De Cecco, G Llort, A Cazorla, N Bonifaci, M J Garcia, T Caldés, I Blanco, M Gariboldi, M A Pierotti, M A Pujana, J Benítez and A Osorio
Br J Cancer 101: 1469-1480; doi:10.1038/sj.bjc.6605275
GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes
V Hoene, M Fischer, A Ivanova, T Wallach, F Berthold and C Dame
Br J Cancer 101: 1481-1489; advance online publication, August 25, 2009; doi:10.1038/sj.bjc.6605276
Letter to the Editor
The mysterious steps in carcinogenesis: addendum
D Brash and J Cairns
Br J Cancer 101: 1490; doi:10.1038/sj.bjc.6605332
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
